

GUIDELINES

1) Statement

Proteomics offers functional insights to the molecular mechanisms governing the disease pathology. Due to technological constraints mass-spectrometry based proteomics was restricted to small-scale, discovery-based research. Biognosys has revolutionized this technology by developing novel, robust, unbiased, and scalable approaches perfectly suited for clinical applications. It is therefore Biognosys' primary objective to introduce next generation proteomics solutions as an integral part of clinical research worldwide.

To achieve this goal, the Biognosys Grant Program was established, which provides access to cutting-edge proteomics solutions to Principal Investigators (PI) involved in clinical research around the globe. Each year the Grant Program focuses on clinical research projects in a different field with unmet medical needs.

2) Application and selection process

Biognosys intends to award the Grant in the medical field where the needs for precision medicine are largely unmet and the understanding of the disease mechanism; hence availability of effective therapy, is limited. The current edition is focusing on clinical research of Non-Alcoholic Fatty Liver Disease (NAFLD) and its progressive variants like Non-Alcoholic Steatohepatitis (NASH).

The application process is administered fully by Biognosys and the applications are reviewed by cross-functional experts. The submission period opens on the 10 December 2020. The application form is available online and should be completed no later than 17 February 2021.

Grant applications should be submitted according to the following guidelines and eligibility criteria:

- Proposals from clinical research area, focusing on therapeutic benefit, mechanism of action or biomarker discovery will be considered with priority.
- Proposals which include clinical sample availability before 01 June 2021 will be prioritized.
- Application must be submitted in English.
- Application must be submitted electronically using the provided platform (<https://biognosys.com/grant-program>).
- The Grant application should include the following:
 - PI identification and affiliation (including CV)
 - Project Title
 - Study Type
 - Trial registration ID (if applicable)
 - Sample information (availability, type, status)
 - Intended study cohort information: orthogonal assays performed, data availability and funding sources
 - Description of the scientific rationale for the study, overall study objectives and project specific objectives (use of proteomics)
 - References

Biognosys will consider applications based on the scientific merit and strategic alignment with Biognosys areas of scientific interest. Applications are reviewed by Biognosys scientific leadership. Notification of selection is expected to be provided within 8 weeks after the closing date. The Grant Awardee and the scope of the project will be publicly announced shortly thereafter. In addition, Biognosys will use the Grant Program for marketing purposes; thus, the receiving party and its organization agrees to be acknowledged in all marketing channels used by Biognosys throughout the duration of the project and beyond.

3) Grant offering

Upon successful evaluation the applicant will be granted access to the Biognosys premium Hyper Reaction Monitoring™ (HRM™) platform for a total of 100 samples, including data analysis.

The following are part of the Grant offering:

- Scientific consulting
- Lab materials pertaining to proteomic analysis performed by Biognosys
- Man-hours and facility resources covering:
 - Sample storage and preparation and processing for HRM™
 - HRM™ analysis
 - Raw data processing and data analysis using Biognosys' latest Spectronaut 14™ software
 - Data Reporting

TERMS AND CONDITIONS

1) Exclusions from grant offering

Biognosys will not fund nor support, among others, items such as:

- Costs of sample delivery and return
- Gifts
- Travel costs
- Salaries and benefits
- Direct sponsorship of participant's expenses

Completion of post-program reconciliation might be required for state/federal/country reporting purposes such as Open Payments (Sunshine Act).

2) Ethics

Biognosys does not take any responsibility for the legal framework applying to the study and project and assumes that all required measures were undertaken by the Principal Investigator and his Team and do comply with the Declaration of Helsinki regulating research on humans. For example, these include, but are not limited to, patient's consent, approval from Ethics Committee and/or Sponsor for the intended use.

3) Confidentiality and conflict of interest

The confidentiality of all submitted applications is guaranteed by Biognosys. All stakeholders involved in evaluation and handling of the proposals are employees of Biognosys and by default are obliged to maintain full confidentiality for the study details and contents of project applications as well as the results of the evaluation.

4) Data ownership policy and authorship for publication

The PI will co-own the data produced during sponsored research. Publication authorship is sole responsibility of the PI and research team. Any publication/communication resulting from the project must acknowledge Biognosys Grant Program and must be available under open access policy. Biognosys reserves the right to review publications prior to submission, correct factual mistakes about our services and products and protect proprietary information. Potential further use of the data by Biognosys will be discussed with the Awardee and will be documented separately.